Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy

NCT02422979 is registered in ClinicalTrials.gov with Rakuten Medical, Inc. as lead sponsor.

NCT NCT02422979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02422979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Lead sponsor
Rakuten Medical, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2015
Completion date
February 25, 2019
Enrollment
40 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent head and neck cancer